Ultragenyx Pharmaceutical (NASDAQ:RARE) Director Shehnaaz Suliman Sells 5,740 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Shehnaaz Suliman sold 5,740 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the transaction, the director directly owned 27,951 shares in the company, valued at approximately $702,129.12. This represents a 17.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ultragenyx Pharmaceutical Stock Down 3.2%

NASDAQ:RARE traded down $0.81 during trading hours on Monday, reaching $24.19. 1,548,682 shares of the stock were exchanged, compared to its average volume of 2,194,542. The firm has a 50 day simple moving average of $23.09 and a 200-day simple moving average of $26.46. The stock has a market capitalization of $2.38 billion, a P/E ratio of -3.96 and a beta of 0.39. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.29 and a 52 week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The company had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.19 million. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The firm’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.57) earnings per share. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.63 earnings per share for the current year.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the company. Assetmark Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank raised its holdings in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,440 shares in the last quarter. Leonteq Securities AG raised its holdings in Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,333 shares in the last quarter. Finally, Danske Bank A S bought a new position in Ultragenyx Pharmaceutical during the third quarter valued at about $39,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently commented on the company. Wells Fargo & Company raised their target price on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. reduced their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research note on Thursday, March 12th. Wall Street Zen lowered Ultragenyx Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. The Goldman Sachs Group cut Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $61.00 to $25.00 in a research report on Tuesday, March 24th. Finally, HC Wainwright decreased their target price on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $60.41.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.